v3.26.1
DECONSOLIDATION OF SUBSIDIARIES (Tables)
 12 Months Ended
Dec. 31, 2024
Restructuring Cost and Reserve [Line Items]  
SCHEDULE OF DECONSOLIDATE ASSETS AND LIABILITIES

The following table summarizes the allocation of purchase price to the fair values of the assets acquired and liabilities assumed as of the Transaction date:

 

   (in thousands) 
Total Contingent consideration to MM for royalty and milestone payments  $4,643 
      
Total assets acquired:     
Cash and cash equivalents  $139 
Property, plants and equipment, net   17,852 
Other Assets   3,478 
Total assets  $21,469 
      
Total liabilities assumed:     
Total current liabilities  $(12,518)
Total long-term liabilities   (5,628)
Total liabilities  $(18,146)
      
Know how Technology   1,728 
      
Total Net Assets  $5,051 
Fair-Value of Non-controlling interests   (408)
Total liability to MM  $4,643 
Orgenesis Biotech Israel Limited [Member]  
Restructuring Cost and Reserve [Line Items]  
SCHEDULE OF DECONSOLIDATE ASSETS AND LIABILITIES

The following table summarizes the deconsolidated assets and liabilities as of February 14, 2024:

 

      
Total assets acquired:     
Cash and cash equivalents  $4 
Property, plants and equipment, net   2,884 
Other Assets   1,422 
Total assets  $4,310 
      
Total liabilities:  $4,244 
Total Net Assets deconsolidated  $66 
Loss from deconsolidation of OBI  $66 

 

 

      
Total assets acquired:     
Cash and cash equivalents  $1 
Property, plants and equipment, net   - 
Other Assets   40 
Total assets  $41 
      
Total liabilities:  $749 
Total Net liabilities deconsolidated  $708 
Total accumulated other comprehensive income deconsolidated  $627 
Profit from deconsolidation of Orgenesis Korea  $1,335